HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Technology evaluation: HYB-2055, Hybridon.

Abstract
Hybridon is developing immunomodulatory oligonucleotides. including injectable HYB-2055 (IMOxine) which acts as an agonist of toll-like receptor 9, for the potential treatment of cancer. HYB-2055 is currently undergoing phase II clinical trials. The immunomodulatory oligonucleotides are also being investigated for the potential treatment of infectious diseases and immune disorders.
AuthorsTomasz Switaj, Witold Lasek
JournalCurrent opinion in molecular therapeutics (Curr Opin Mol Ther) Vol. 7 Issue 4 Pg. 376-83 (Aug 2005) ISSN: 1464-8431 [Print] England
PMID16121704 (Publication Type: Journal Article)
Chemical References
  • HYB-2055
  • Immunologic Factors
  • Oligonucleotides
Topics
  • Animals
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Communicable Diseases (drug therapy)
  • Humans
  • Immune System Diseases (drug therapy)
  • Immunologic Factors (therapeutic use)
  • Injections
  • Mice
  • Neoplasms (drug therapy)
  • Oligonucleotides (adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: